WFRF:(Kjeldsen Sverre)
Sökning: WFRF:(Kjeldsen Sverre) > (2015-2019) > Which Target Blood ...
Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials
-
- Heimark, Sondre (författare)
- Diakonhjemmet Hospital
-
- Mariampillai, Julian E. (författare)
- Oslo university hospital
-
- Narkiewicz, Krzysztof (författare)
- Medical University of Gdansk
- visa fler...
- visa färre...
- (creator_code:org_t)
- 2018-04-16
- 2018
- Engelska 8 s.
- Ingår i: High Blood Pressure and Cardiovascular Prevention. - : Springer Science and Business Media LLC. - 1120-9879 .- 1179-1985. ; 25:2, s. 151-158
- Forskningsöversikt (refereegranskat)
Abstract
Ämnesord
Stäng
- The Systolic Blood Pressure Intervention Trial (SPRINT) suggested a favourable effect of lowering blood pressure to < 120/80 mmHg in high-risk hypertensive patients; however, new American guidelines in 2017 have not followed SPRINT but lowered its recommended treatment target to < 130/80 mmHg. We aimed to review the latest research from large randomised controlled trials and observational analyses in order to investigate the evidence for new treatment targets. We assessed recent data from the Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD) study, the International Verapamil-Trandolapril Study (INVEST), the Telmisartan, Ramipril or Both in Patients at High Risk for Vascular Events trial (ONTARGET)/the Telmisartan Randomised AssessmenNt Study in aCE iNtolerant participants with cardiovascular Disease (TRANSCEND) study and The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. These studies confirm a positive effect on cardiovascular protection with blood pressure lowering treatment to between 120–140 mmHg in patients with and without diabetes, but no additional effect of lowering blood pressure to < 120 mmHg; possibly too aggressive treatment may increase both cardiovascular morbidity and mortality. Thus, a target blood pressure < 130/80 mmHg appears appropriate in most high-risk hypertensive patients. Additionally, early and sustained BP control below this target is required for optimal cardiovascular protection.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Antihypertensive drug-treatment
- Antihypertensive therapy
- Blood pressure measurement
- Blood pressure target
- Cardiovascular disease
- Hypertension
- Randomized controlled trial
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
- High Blood Pressure and Cardiovascular Prevention (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Heimark, Sondre
- Mariampillai, Ju ...
- Narkiewicz, Krzy ...
- Nilsson, Peter M ...
- Kjeldsen, Sverre ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- High Blood Press ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
